Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190331133 | Oral cavity | NEOLP | regulation of mRNA metabolic process | 91/2005 | 288/18723 | 2.65e-22 | 7.88e-19 | 91 |
GO:000640232 | Oral cavity | NEOLP | mRNA catabolic process | 62/2005 | 232/18723 | 5.51e-12 | 9.91e-10 | 62 |
GO:000641734 | Oral cavity | NEOLP | regulation of translation | 97/2005 | 468/18723 | 9.94e-11 | 1.05e-08 | 97 |
GO:006101332 | Oral cavity | NEOLP | regulation of mRNA catabolic process | 45/2005 | 166/18723 | 2.67e-09 | 1.64e-07 | 45 |
GO:000640131 | Oral cavity | NEOLP | RNA catabolic process | 63/2005 | 278/18723 | 5.63e-09 | 3.07e-07 | 63 |
GO:190331233 | Oral cavity | NEOLP | negative regulation of mRNA metabolic process | 28/2005 | 92/18723 | 1.92e-07 | 6.49e-06 | 28 |
GO:003465531 | Oral cavity | NEOLP | nucleobase-containing compound catabolic process | 73/2005 | 407/18723 | 6.69e-06 | 1.34e-04 | 73 |
GO:003133034 | Oral cavity | NEOLP | negative regulation of cellular catabolic process | 52/2005 | 262/18723 | 8.04e-06 | 1.57e-04 | 52 |
GO:000989533 | Oral cavity | NEOLP | negative regulation of catabolic process | 59/2005 | 320/18723 | 2.16e-05 | 3.57e-04 | 59 |
GO:003090013 | Oral cavity | NEOLP | forebrain development | 67/2005 | 379/18723 | 2.54e-05 | 3.99e-04 | 67 |
GO:004670031 | Oral cavity | NEOLP | heterocycle catabolic process | 75/2005 | 445/18723 | 4.61e-05 | 6.38e-04 | 75 |
GO:190237313 | Oral cavity | NEOLP | negative regulation of mRNA catabolic process | 18/2005 | 63/18723 | 7.26e-05 | 9.41e-04 | 18 |
GO:190236931 | Oral cavity | NEOLP | negative regulation of RNA catabolic process | 20/2005 | 75/18723 | 8.63e-05 | 1.07e-03 | 20 |
GO:000095631 | Oral cavity | NEOLP | nuclear-transcribed mRNA catabolic process | 26/2005 | 112/18723 | 1.06e-04 | 1.28e-03 | 26 |
GO:004427031 | Oral cavity | NEOLP | cellular nitrogen compound catabolic process | 74/2005 | 451/18723 | 1.24e-04 | 1.47e-03 | 74 |
GO:001943931 | Oral cavity | NEOLP | aromatic compound catabolic process | 75/2005 | 467/18723 | 2.22e-04 | 2.34e-03 | 75 |
GO:000641431 | Oral cavity | NEOLP | translational elongation | 15/2005 | 55/18723 | 4.94e-04 | 4.39e-03 | 15 |
GO:190136131 | Oral cavity | NEOLP | organic cyclic compound catabolic process | 77/2005 | 495/18723 | 4.96e-04 | 4.40e-03 | 77 |
GO:000018431 | Oral cavity | NEOLP | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 11/2005 | 37/18723 | 1.26e-03 | 9.21e-03 | 11 |
GO:00215371 | Oral cavity | NEOLP | telencephalon development | 40/2005 | 248/18723 | 5.50e-03 | 2.93e-02 | 40 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SECISBP2 | SNV | Missense_Mutation | rs147681365 | c.1720N>A | p.Glu574Lys | p.E574K | Q96T21 | protein_coding | tolerated(0.7) | benign(0.01) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SECISBP2 | SNV | Missense_Mutation | | c.92N>G | p.Asn31Ser | p.N31S | Q96T21 | protein_coding | tolerated(0.44) | benign(0.007) | TCGA-E9-A1RE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
SECISBP2 | SNV | Missense_Mutation | novel | c.2057N>C | p.Leu686Pro | p.L686P | Q96T21 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-GM-A3NY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SECISBP2 | insertion | Nonsense_Mutation | novel | c.572_573insTAGCTCCGGAAATTAACAGAAACATTTGCTGGAAGGAGG | p.Ser191_Asp192insSerSerGlyAsnTerGlnLysHisLeuLeuGluGlyGly | p.S191_D192insSSGN*QKHLLEGG | Q96T21 | protein_coding | | | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SECISBP2 | SNV | Missense_Mutation | novel | c.158N>C | p.Phe53Ser | p.F53S | Q96T21 | protein_coding | tolerated(0.06) | benign(0.348) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SECISBP2 | SNV | Missense_Mutation | novel | c.2011N>T | p.Arg671Cys | p.R671C | Q96T21 | protein_coding | deleterious(0) | possibly_damaging(0.906) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SECISBP2 | SNV | Missense_Mutation | | c.2464N>A | p.Glu822Lys | p.E822K | Q96T21 | protein_coding | tolerated(1) | benign(0.02) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
SECISBP2 | SNV | Missense_Mutation | | c.1863N>G | p.Phe621Leu | p.F621L | Q96T21 | protein_coding | tolerated(1) | benign(0) | TCGA-EX-A69M-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
SECISBP2 | SNV | Missense_Mutation | | c.2146G>A | p.Asp716Asn | p.D716N | Q96T21 | protein_coding | tolerated(0.05) | probably_damaging(0.999) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SECISBP2 | insertion | In_Frame_Ins | novel | c.1619_1633dupGGCAAGAGAGAAAGC | p.Arg540_Lys544dup | p.R540_K544dup | Q96T21 | protein_coding | | | TCGA-JW-AAVH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |